• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Co-Diagnostics Inc.

    1/21/26 4:15:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on January 21, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    CO-DIAGNOSTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Utah   46-2609396
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    2401 S. Foothill Drive, Suite D

    Salt Lake City, Utah 84108

    (Address of Principal Executive Offices) (Zip Code)

     

    Co-Diagnostics, Inc. 2025 Equity Incentive Plan

    (Full title of the plan)

     

    Brian Brown

    Chief Financial Officer

    Co-Diagnostics, Inc.

    2401 S. Foothill Drive

    Salt Lake City, Utah 84109

    (Name and address of agent for service)

     

    (385) 831-7576

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    Copies to:

     

    Kevin Ontiveros, Esq.   David F. Marx
    General Counsel   Daniel P. Lyman

    2401 S. Foothill Drive

    Salt Lake City, Utah 84109

    Telephone: (801) 450-7001

     

    Dorsey & Whitney LLP

    111 South Main Street, Suite 2100

    Salt Lake City, Utah 84111

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in “Item 1. Plan Information” and “Item 2. Registrant Information and Employee Plan Annual Information” of Form S-8 will be sent or given to participants of the Co-Diagnostics, Inc. 2025 Equity Incentive Plan, as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the Securities and Exchange Commission either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    There are hereby incorporated by reference in this Registration Statement of Co-Diagnostics, Inc., a Utah corporation (the “Company” or the “Registrant”) the following documents and information heretofore filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) with the Securities and Exchange Commission:

     

      ● The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025;
         
      ● The Company’s Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025;
         
      ● The Company’s Current Reports on Form 8-K filed with the SEC on January 10, 2025, February 21, 2025, April 28, 2025, May 29, 2025; July 11, 2025, September 18, 2025, October 20, 2025, October 29, 2025, December 5, 2025, December 30, 2025, and January 13, 2026;
         
      ● The description of the Company’s common stock, which is contained in the Registration Statement on Form 8-A, as filed with the SEC on July 11, 2017, pursuant to Section 12(b) of the Exchange Act, as updated by the description of our Common Stock contained in Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025, including any amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this registration statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of common stock registered hereunder have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Item 2.02 or 7.01 or any related Item 9.01 of Form 8-K that is not deemed filed under such provisions.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    You may request a copy of these filings, at no cost, by writing or telephoning the Company at:

     

    Co-Diagnostics, Inc.

    2401 S. Foothill Drive

    Salt Lake City, Utah 84109

    Telephone: (801) 438-1036.

    Attention: Investor Relations

     

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Company has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant’s Articles of Incorporation provide that to the fullest extent permitted by the Registrant’s bylaws (the “Bylaws”) or the Utah Revised Business Corporation Act, as amended (the “Act”), or any other applicable law, as either may be amended, a director shall have no liability to the Registrant or its shareholders for monetary damages for conduct, any action taken, or any failure to take any action as a director. As permitted by the Act, directors will not be personally liable to the Registrant or the Registrant’s shareholders for monetary damages for any action taken or any failure to take action as a director except liability for (a) the amount of a financial benefit received by a director to which he is not entitled; (b) an intentional infliction of harm on the Registrant or its shareholders; (c) an unlawful distribution in violation of Section 16-10a-842 of the Act; or (d) an intentional violation of criminal law.

     

    These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies, such as an injunction or rescission.

     

    In addition, the Bylaws provide that:

     

      ● the Registrant will indemnify its directors to the fullest extent permitted by the Act, including advancing expenses in connection with legal proceedings, subject to limited exceptions; and
         
      ● the Registrant may, to the extent permitted by the Act, by action of its board of directors, agree to indemnify officers, employees and other agents of the Registrant and may advance expenses to such persons.

     

    The Registrant has entered into indemnification agreements with each of the Registrant’s executive officers and directors. These agreements provide that, subject to limited exceptions and among other things, the Registrant will indemnify each of its executive officers and directors to the fullest extent permitted by law and advance expenses to each indemnity in connection with any proceeding in which a right to indemnification is available.

     

    The Registrant maintains general liability insurance that covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons who control the Registrant, the Registrant has been informed that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    These provisions may discourage shareholders from bringing a lawsuit against the Registrant’s directors for breach of their fiduciary duty, or may have the practical effect in some cases of eliminating the Registrant’s shareholders’ ability to collect monetary damages from its directors and officers. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit the Registrant and its shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent the Registrant pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

     

    Item 7. Exemption From Registration Claimed.

     

    Not applicable.

     

     

     

     

    Item 8. Exhibits

     

    The following exhibits are filed herewith or incorporated herein by reference.

     

    Exhibit

    Number

      Exhibit Description  

    Filed with this

    Report

     

    Incorporated by

    Reference herein from Form or Schedule

      Filing Date  

    SEC File/Reg.

    Number

    3.1   Articles of Incorporation       Draft Registration Statement (Exhibit 3.1)   01/12/17   377-01467
                         
    3.1.1   Amendment to the Articles of Incorporation       Draft Registration Statement (Exhibit 3.1.1)   01/12/17   377-01467
                         
    3.1.2   Articles of Amendment to Articles of Incorporation       Form 8-K (Exhibit 3.2)   01/03/19   001-38148
                         
    3.1.3   Articles of Amendment       Form 10-K (Exhibit 3.1.3)   03/24/22   001-38148
                         
    3.1.4   Articles of Amendment       Form 8-K (Exhibit 3.1)   12/30/25   001-38148
                         
    3.2   Amended and Restated Bylaws of Co-Diagnostics, Inc.       Form 10-K (Exhibit 3.2)   03/27/25   001-38148
                         
    10.1   Co-Diagnostics, Inc. 2025 Equity Incentive Plan   X            
                         
    5.1   Opinion of Legal Counsel   X            
                         
    23.1   Consent of Independent Registered Public Accounting Firm,   X            
                         
    23.2   Consent of Counsel (included in Exhibit 5.1)   X            
                         
    24.1   Power of Attorney (included in signature page)   X            
                         
    107   Filing Fee Table   X            

     

    * Filed herewith.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);
         
      (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Salt Lake City, Utah, on this 21st day of January, 2026.

     

      CO-DIAGNOSTICS, INC.
       
      BY: /s/ Dwight Egan
        Dwight Egan
       

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

     

    Each person whose signature appears below constitutes and appoints Dwight Egan and Brian Brown, and each of them singly, her or his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them singly, for her or him and in her or his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Co-Diagnostics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    NAME AND SIGNATURE   TITLE   DATE
             
    /s/ Dwight Egan        
    Dwight Egan   Chief Executive Officer, President and Director   January 21, 2026
        (Principal Executive Officer)    
    /s/ Brian Brown        
    Brian Brown  

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      January 21, 2026
             
    /s/ Eugene Durenard        
    Eugene Durenard   Director   January 21, 2026
             
    /s/ Edward Murphy        
    Edward Murphy   Director   January 21, 2026
             
    /s/ James Nelson        
    James Nelson   Director   January 21, 2026
             
    /s/ Richard Serbin        
    Richard Serbin   Director   January 21, 2026

     

     

    Get the next $CODX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

    SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences. The events provided opportunities for CoSara to introduce its SARAGENE® diagnos

    1/12/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Announces Reverse Stock Split

    SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx's common stock will continue to trade on The Nasdaq Capital Market under the symbol "CODX" and will begin trading on a split-adjusted basis when the market opens on Friday, January

    12/30/25 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

    The Australian patent represents the first patent granted for the Company's new point-of-care testing platform SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*. Initially filed in May 2022 before being granted i

    12/29/25 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Murphy Edward L. was granted 57,499 shares, increasing direct ownership by 26% to 281,666 units (SEC Form 4)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    11/24/25 5:47:27 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brown Brian Lee was granted 134,167 shares and returned $14,253 worth of shares to the company (40,723 units at $0.35), increasing direct ownership by 18% to 599,355 units (SEC Form 4)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    11/24/25 5:31:40 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    President Abbott Richard David returned $6,020 worth of shares to the company (17,200 units at $0.35) and was granted 56,667 shares, increasing direct ownership by 148% to 66,202 units (SEC Form 4)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    11/24/25 5:31:21 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    SEC Filings

    View All

    SEC Form S-8 filed by Co-Diagnostics Inc.

    S-8 - Co-Diagnostics, Inc. (0001692415) (Filer)

    1/21/26 4:15:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

    1/13/26 12:23:23 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

    12/30/25 9:15:26 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Co-Diagnostics downgraded by Sidoti with a new price target

    Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

    8/12/22 9:07:51 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Sidoti initiated coverage on Co-Diagnostics with a new price target

    Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

    12/29/21 8:45:34 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

    HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

    11/12/21 6:13:11 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

    SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

    4/4/24 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

    SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

    8/29/23 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

    SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf

    11/1/22 9:32:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Financials

    Live finance-specific insights

    View All

    Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

    SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    10/31/25 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

    SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Revenue of $0.2 million, which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the second quarter of 2025Operating expenses of approximately $8.2 million decreased by 19.1%

    8/14/25 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

    SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    7/31/25 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/13/24 5:02:32 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/9/22 3:43:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    7/12/21 8:29:19 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care